Your SlideShare is downloading. ×
  • Like
"Evidence Matters When it Comes to Health: A New Tool of ...
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

"Evidence Matters When it Comes to Health: A New Tool of ...

  • 525 views
Published

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
525
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • Over ten years experience designing world-class marketing and PR for a wide array of offline and online brands. She is president of Armada Global Inc. a marketing firm in San Francisco
  • Overhead: quote re in 2yrs solutions will be analysis of information available (perhaps put this at end)
  • Not machine translation. Several thousand vocabulary elements to translate – takes about a month or two to add a new language
  • Not machine translation. Several thousand vocabulary elements to translate – takes about a month or two to add a new language
  • 1) EMB online search engines have legacy systems that cannot be adapted to our methods and are underfunded; MDConsult has good institution penetration but its revenue model and unscaleable offerings limit its strategy 2) Portable devices are a unique competitor category, the only one of which we know to be achieving serious penetration is ePocrates. They are the one we most need to beat to this market. 3) The eHealth portals such as the content branch of WebMD etc would stand the best chance in principle of competing directly with us. However, they are all struggling fairly unsuccessfully to meet their own core competencies. With $1B in the bank WebMD would most likely provide us with a good exit strategy if we prove our concept and attract eyeballs. 4) The5 big Cos would be cannibalizing their core business by creating a service like ours, since their bread and butter is providing new protocols & research. 5) Similar for the offline publishers; their business is publishing as much research as possible. they are large public companies with fair cash reserves. They are staid institutions however, slow to change 6) HMOs and hospitals are all currently in their first or second year of installing internal databases to conduct internal outcomes research to see how effective & cost-effective their therapies are in the real world. They are therefore creating an enormous volume of data that is complimentary to the more pure clinical research studies and is level () evidence. [overhead of 10 levels] In fact, an HMO would be very interested in acquiring our tool as a service both for it’s physicians, as well as a free web service to market to potential patients. I have had interest expressed by an HMO, an informatics company, and a member of the board of directors of a big pharma co 7) Big pharma would be interested in our tool as well, both as a service to market to MDs, to patients, and for internal use for its own research planning. They could be a source of extra income to fund initiatives to code in more basic science research, especially as the explosion of information from genomics starts to come in. (next slide: What we've done so far)
  • Overhead: quote re in 2yrs solutions will be analysis of information available (perhaps put this at end)
  • Overhead: quote re in 2yrs solutions will be analysis of information available (perhaps put this at end)
  • Overhead: quote re in 2yrs solutions will be analysis of information available (perhaps put this at end)
  • EM will earn revenue from at least 8 sources: 1)     We give away the database with entries up to 1998-9 for free. Clinicians and consumers will pay to have the up-to-date version (updated weekly or daily), to use added-value features (such as an up-to-date database) after the first year. As opposed to 240-1200$US annually for other, less robust services, we will charge $200US per clinician annually. Users may also pay to read premium content (i.e. full journal articles), or to have resources (e.g. Patient handouts or studies) mailed directly to someone they care about. 2)      Institutions that currently pay for evidence-based informatics services (like MD Consult) will pay a competitive ASP fee 3)      It will license its novel content (news, rankings, and graphical interface) to health institutions, libraries, drug companies, and web portals. (Already have interest from Mayo site and Medem site for medical specialties) 4)      We can charge for extra features such as access to full-text articles 5)      We can take a commission for features such as funds donated to specific research groups through our site 6)      Ecommerce affiliate program links (as CNET does) for consumer products including orthopedic aids and over-the-counter drugs from vendors such as Drugstore.com 7)      There will be a comprehensive database of anonymous health-seeking question information created that may sold to market researchers. 8) We will strive to avoid making advertising a significant revenue source, unless it is in the form of unrestricted grants for development, to avoid the potential for bias, or the perception of. We may eventually earn money through advertising, if market research shows this is acceptable to consumers (we must maintain the appearance of and de facto impartiality). Limited Palm-pilot based advertising for MDs may be more acceptable - (next slide competitive advantages)

Transcript

  • 1. Cover Slide Evidence Matters! KU-03 2003, Quebec, Canada Ofer Allan Avital M.D., Anne Bourbonnais RN, MSc (cand) Founders, Evidence Matters [email_address]
  • 2. Our Scientific Advisors
    • Stuart Macleod M.D . - former dean of medicine at McMaster university
    • Mo Watanabe , M.D . – former dean of medicine, University of Calgary, EBM Expert
    • Dr. Lewis Slotin – Former Director, MRC
    • Dr. Al Shrier – Chair of McGill Physiology Dept
    • Angela Lambrou , MSLIS , Librarian, McGill U
    • Louise Bourbonnais , MSLIS , Librarian, IUGM
  • 3. Outline Presentation Outline
    • The Problems With Evidence
    • Current Resources
    • Example of a Clinical Question
    • Accolades, Awards & Activities
    • How to Access
    - Evidence Matters
  • 4. Example of a Clinical Question A Clinician or Manager Asks: For a 35 year old woman with breast cancer (with bone metastases), what are the therapies available with: Goal : Include multiple types of research designs, organized by level of evidence - Highest remission rates at five years? - Lowest nausea rates during therapy? - Least hair loss? - Outcomes above and lowest costs?
  • 5. Outline Presentation Outline
    • The Problems With Evidence
    • Current Resources
    • Example of a Clinical Question
    • Accolades, Awards & Activities
    • How To Access
    - Evidence Matters The Problem With Finding Evidence
  • 6. Outline Challenges - Philosophical
    • Leave room for experience, judgment
    • Evidence can sometimes be rigid
    • Evidence should inform, not dictate
    The Problem With Finding Evidence
  • 7. Outline Challenges - Practical
    • Evidence can be slow/hard to synthesize
    • Varying levels of evidence
    • Evidence can be slow/hard to amass
    • Timeliness of synthesized resources vary
    • No standardization of outcomes
    - Contradictory findings The Problem With Finding Evidence
  • 8. Outline Presentation Outline
    • The Problem With Finding Evidence
    • Current Resources
    • Example of a Clinical Question
    • Accolades, Awards & Activities
    • How To Access
    - Evidence Matters
  • 9. Spectrum of Professional Literature Research Resources
    • Medline/Pubmed
    Find - Index Medicus - Library Collections
    • Evidence Matters
    Read Synthesize Apply - Text - Article Summaries (“ Metagraph ”) - Expert/Researcher (+/- evidence) Construct Question “ Metaanalysis ” Can “Drill-down” to get - Reference Lists Choose Concept Term Do above Choose Concept/Keyword Do above Ask a Question Customized Answer
  • 10. Spectrum of Professional Literature The Spectrum of Professional Literature MDConsult Harrison’s Online
    • Graph Summary Views
    UpToDate Evidence Matters - Multiple types of research - Daily Updates
    • Multilingual
    • Summaries of every article
    Cochrane ACP Clinical Evidence
      • User-defined
      • Outcomes-based
    Medline Traditional Opinion Evidence-Based Cancer Focus
  • 11. Outline Presentation Outline
    • The Problem With Finding Evidence
    • Current Resources
    • Example of a Clinical Question
    • Accolades, Awards & Activities
    • How To Access
    - Evidence Matters
  • 12. Home Page & Login DrKoop
  • 13. Graph 1 – Intro: All therapies Search! Answer:
  • 14. Graph 1b - Level of Evidence
  • 15. Graph 1c - Case Series Label
  • 16. Graph 1d - Legend & Drill Down
  • 17. List View 1
  • 18. List View 2
  • 19. Article Summary 1a - Recurrence Outcome
  • 20. Article Summary 1b - Other Outcomes
  • 21. Article Summary 1a - Recurrence Outcome
  • 22. Article Summary 1c - Scroll Down
  • 23. Construct new Question/Search
  • 24. Question Wizard - Step 1a
  • 25. Question Wizard - Step 1b
  • 26. Question Wizard - Step 2a
  • 27. Question Wizard - Step 2a1
  • 28. Question Wizard - Step 2b1
  • 29. Question Wizard - Step 2b2
  • 30. Question Wizard - Step 2b2-P
  • 31. Question Wizard - Step 3
  • 32. Question Wizard - Step 3a
  • 33. Question Wizard - Step 3b
  • 34. Question Wizard - Step 3b6
  • 35. Question Wizard - Step 3b62
  • 36. Question Wizard - Step 3b62b
  • 37. Question Wizard - Step 3b62b-OverallS
  • 38. Question Wizard - Generate Graph
  • 39. Graph 2 - Prednisone Prednisone
  • 40. Favorites
  • 41. EM Feature Summary - Graph Summary Views Feature Summary - Multiple types of research - Daily Updates - User-defined comparisons
    • Multilingual
    • Summaries of every article
    - Outcomes-based
  • 42. Outline Presentation Outline
    • The Problem With Finding Evidence
    • Current Resources
    • Example of a Clinical Question
    • Accolades, Awards & Activities
    • How To Access
    - Evidence Matters
  • 43. Accolades from Test Users « This is the most time-friendly device for medical information I’ve ever seen » « I cannot believe this will not become the new standard of care » « I find it hard to get medical articles from the MEDLINE database, but this is easy and fast » Dr. George Michaels Assistant professor Family Medicine McGill University, Assistant Physician-in-Chief St-Mary’s Hospital Dr. Campbell Davies, Gastroenterologist, St. Mary’s Hospital
  • 44. Awards • Finalist for Best New Company in Canada, Canadian Youth Business Foundation • December 2002: $350 000 Federal grant signed from CANARIE • Financial backing from MedTech Partners inc. 2003 2002 • Best Company – Samson Belair Deloitte Touche Investors night - $5 000 prize 2001 • Governor’s Circle : Best New Company - $20 000 grant from City of Montreal, “Fondation du Maire de Montreal”
  • 45. Activities - 2003 • CHLA 2003, EBL, in Edmonton, Alberta. Paper presentation, Poster September June • KU-03: Knowledge Utilization / Transfer Colloquium, KU-UC/CHSRF/CIHR, Invited Speaker February • TEKT Think Tank, CIHR - Vancouver, B.C. • McGill Medical Class - Invited Speaker, class on Evidence Based Medicine • USMLA 2003, San Diego. Registrant
  • 46. Outline Presentation Outline
    • The Problem With Finding Evidence
    • Current Resources
    • Example of a Clinical Question
    • Accolades, Awards & Activities
    • How To Access
    - Evidence Matters
  • 47. Access to Our System
    • 1) Free Trials available in 3-6 months
    2) Some Content always free 4) Browser-based (no installation) 3) Subscription to the rest Questions : [email_address] 5) Leave your contact information or contact us to be notified of the launch and trials
  • 48. End